http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113046314-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
| filingDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113046314-B |
| titleOfInvention | A method for inducing and expanding decidual-like natural killer cells from human umbilical cord blood or bone marrow hematopoietic stem cells in vitro |
| abstract | This application discloses a method for inducing and expanding decidual-like natural killer cells from hematopoietic stem cells in vitro, comprising: culturing CD34 + hematopoietic stem cells in vitro in four stages, wherein stage I is the expansion of CD34 + hematopoietic stem cells, and stage II In order to induce the differentiation of CD34 + hematopoietic stem cells to NK cell precursors, stage III is to induce the differentiation of NK cell precursors to NK cells, and stage IV is to induce the expansion and maturation of NK cells, and collect CD3 ‑ CD56 + NK cells to obtain deciduous Membrane-like natural killer cells, wherein the culture starts with fresh basal medium containing cytokine combination I, and uses cytokine combination I, combination II, combination III and combination IV in stages I, II, III and IV of the culture, respectively The fresh basal medium of the above-mentioned medium is carried out half amount exchange culture, wherein said cytokine combination I is Flt3L and SCF; Combination II is Flt3L, SCF and IL-15; Combination III is Flt3L, SCF and IL-15; Combination IV is IL-15 15. |
| priorityDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.